CNTX-2022

CNTX-2022 is a high-concentration (40%) topical lidocaine gel formulation developed by Centrexion Therapeutics for the management of acute pain associated with herpes zoster (shingles). Lidocaine is a well-established local anesthetic that functions by blocking voltage-gated sodium channels in neuronal membranes. By inhibiting the influx of sodium ions, lidocaine prevents the initiation and conduction of nerve impulses, thereby providing analgesic effects. CNTX-2022 is specifically designed to deliver a high dose of lidocaine through the skin to reach the underlying peripheral nerves affected by the varicella-zoster virus, aiming to provide more effective pain relief than lower-concentration topical treatments like patches or standard gels. The formulation is intended to provide rapid and deep penetration to target the peripheral nerve endings responsible for acute shingles pain.

Other names

lidocaine 40% gel40% lidocaine gel